$0.10 Earnings Per Share Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter

Equities analysts expect that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will post $0.10 earnings per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for AMAG Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at $0.50. AMAG Pharmaceuticals posted earnings per share of $1.52 in the same quarter last year, which suggests a negative year over year growth rate of 93.4%. The company is expected to issue its next quarterly earnings results on Tuesday, February 13th.

According to Zacks, analysts expect that AMAG Pharmaceuticals will report full-year earnings of ($4.17) per share for the current fiscal year, with EPS estimates ranging from ($6.63) to ($1.43). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.33) per share, with EPS estimates ranging from ($6.91) to ($0.36). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow AMAG Pharmaceuticals.

AMAG has been the subject of a number of analyst reports. Janney Montgomery Scott reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Monday, October 23rd. Zacks Investment Research lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Morgan Stanley initiated coverage on AMAG Pharmaceuticals in a research note on Friday, September 8th. They set an “overweight” rating and a $26.00 target price on the stock. Cantor Fitzgerald reiterated a “hold” rating and set a $21.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. Finally, Jefferies Group reiterated a “buy” rating and set a $16.00 target price on shares of AMAG Pharmaceuticals in a research note on Sunday, November 5th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the company. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $21.58.

AMAG Pharmaceuticals (AMAG) opened at $14.55 on Wednesday. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $36.60. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. The firm has a market capitalization of $523.54, a P/E ratio of -2.39 and a beta of 0.79.

Several hedge funds have recently added to or reduced their stakes in AMAG. State Street Corp boosted its stake in shares of AMAG Pharmaceuticals by 10.6% in the 2nd quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock worth $51,336,000 after buying an additional 267,873 shares during the last quarter. Tocqueville Asset Management L.P. purchased a new position in shares of AMAG Pharmaceuticals in the 3rd quarter worth $3,958,000. Prudential Financial Inc. boosted its stake in shares of AMAG Pharmaceuticals by 59.2% in the 2nd quarter. Prudential Financial Inc. now owns 534,697 shares of the specialty pharmaceutical company’s stock worth $9,839,000 after buying an additional 198,850 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of AMAG Pharmaceuticals by 18.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock worth $22,361,000 after buying an additional 189,576 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of AMAG Pharmaceuticals by 46.1% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 424,875 shares of the specialty pharmaceutical company’s stock worth $7,839,000 after buying an additional 134,080 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://weekherald.com/2018/01/21/0-10-earnings-per-share-expected-for-amag-pharmaceuticals-inc-amag-this-quarter.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply